Abstract
Insulin analysis is used in combination with glucose, C-peptide, beta-hydroxybutyrate, and proinsulin determination for the investigation of adult hypoglycemia. The most common cause is the administration of too much insulin or insulin secretagogue to a diabetic patient or inadequate caloric intake after administration of either. Occasionally there is a question as to whether hypoglycemia has been caused by an exogenous insulin—whether by accident, intent, or even malicious intent. While traditionally this was confirmed by a low or undetectable C-peptide in a hypoglycemic specimen, this finding is not entirely specific and would also be expected in the context of impaired counter-regulatory response, fatty acid oxidation defects, and liver failure—though beta-hydroxybutyrate levels can lend diagnostic clarity. For this reason, insulin is often requested. However, popular automated chemiluminescent immunoassays for insulin have distinctly heterogeneous performance in detecting analogue synthetic insulins with cross-reactivities ranging from near 0 % to greater than 100 %. The ability to detect synthetic insulins is vendor-specific and varies between insulin products. Liquid Chromatography and Tandem Mass Spectrometry (LC-MS/MS) offers a means to circumvent these analytical issues and both quantify synthetic insulins and identify the specific type. We present an immunoaffinity extraction and LC-MS/MS method capable of independent identification and quantitation of native sequence insulins (endogenous, Insulin Regular, Insulin NPH), and analogues Glargine, Lispro, Detemir, and Aspart with an analytical sensitivity for endogenous insulin of between 1 and 2 μU/mL in patient serum samples.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER, Service FJ (2009) Evaluation and management of adult hypoglycemic disorders: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 94(3):709–728
Fukuda I, Hizuka N, Ishikawa Y, Yasumoto K, Murakami Y, Sata A, Morita J, Kurimoto M, Okubo Y, Takano K (2006) Clinical features of insulin-like growth factor-II producing non-islet-cell tumor hypoglycemia. Growth Horm IGF Res 16(4):211–216
Owen WE, Roberts WL (2004) Cross-reactivity of three recombinant insulin analogs with five commercial insulin immunoassays. Clin Chem 50(1):257–259
Heald A, Bhattacharya B, Cooper H, Ullah A, McCulloch A, Smellie S, Wark G (2006) Most commercial insulin assays fail to detect recombinant insulin analogues. Ann Clin Biochem 43(4):306–308
Heurtault B, Reix N, Meyer N, Gasser F, Wendling MJ, Ratomponirina C, Jeandidier N, Sapin R, Agin A (2014) Extensive study of human insulin immunoassays: promises and pitfalls for insulin analogue detection and quantification. Clin Chem Lab Med 52(3):355–362
Thevis M, Thomas A, Delahaut P, Bosseloir A, Schänzer W (2005) Qualitative determination of synthetic analogues of insulin in human plasma by immunoaffinity purification and liquid chromatography-tandem mass spectrometry for doping control purposes. Anal Chem 77(11):3579–3585
Thevis M, Thomas A, Schänzer W, Östman P, Ojanperä I (2012) Measuring insulin in human vitreous humour using lc-ms/ms. Drug Test Anal 4(1):53–56
Thevis M, Thomas A, Delahaut P, Bosseloir A, Schänzer W (2006) Doping control analysis of intact rapid-acting insulin analogues in human urine by liquid chromatography-tandem mass spectrometry. Anal Chem 78(6):1897–1903
Thevis M, Thomas A, Schänzer W (2008) Mass spectrometric determination of insulins and their degradation products in sports drug testing. Mass Spectrom Rev 27(1):35–50
Oran PE, Jarvis JW, Borges CR, Sherma ND, Nelson RW (2011) Mass spectrometric immunoassay of intact insulin and related variants for population proteomics studies. Proteomics Clin Appl 5(7–8):454–459
Peterman S, Niederkofler EE, Phillips DA, Krastins B, Kiernan UA, Tubbs KA, Nedelkov D, Prakash A, Vogelsang MS, Schoeder T et al (2014) An automated, high-throughput method for targeted quantification of intact insulin and its therapeutic analogs in human serum or plasma coupling mass spectrometric immunoassay with high resolution and accurate mass detection (msia-hr/am). Proteomics 14(12):1445–1456
Chen Z, Caulfield MP, McPhaul MJ, Reitz RE, Taylor SW, Clarke NJ (2013) Quantitative insulin analysis using liquid chromatography–tandem mass spectrometry in a high-throughput clinical laboratory. Clin Chem 59(9):1349–1356
Chambers EE, Fountain KJ, Smith N, Ashraf L, Karalliedde J, Cowan D, Legido-Quigley C (2013) Multidimensional lc-ms/ms enables simultaneous quantification of intact human insulin and five recombinant analogs in human plasma. Anal Chem 86(1):694–702
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Van Der Gugten, J.G., Wong, S., Holmes, D.T. (2016). Quantitation of Insulin Analogues in Serum Using Immunoaffinity Extraction, Liquid Chromatography, and Tandem Mass Spectrometry. In: Garg, U. (eds) Clinical Applications of Mass Spectrometry in Biomolecular Analysis. Methods in Molecular Biology, vol 1378. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3182-8_14
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3182-8_14
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3181-1
Online ISBN: 978-1-4939-3182-8
eBook Packages: Springer Protocols